Results 251 to 260 of about 16,510 (292)

Ophthalmic migraines and combined hormonal contraceptives

Contraception, 2011
A 31-year-old G0P0 with a history of migraine-like visual disturbances presented to my office requesting a refill for oral contraceptives. The patient reported one migraine headache at age 11 that was preceded by a blind spot in her vision lasting 30 min. These symptoms did not recur until age 28 when she experienced a visual disturbance described as a
Misa, Perron-Burdick, Courtney, Schreiber, Pratima, Gupta   +2 more
openaire   +2 more sources

Impact of combined hormonal contraceptives on vessels functionality

Archives of Gynecology and Obstetrics, 2016
To evaluate the dynamic and static retinal vascular functionality in young females using combined hormonal contraceptive (CHC).Thirty-eight consecutive young female subjects were enrolled in this study between January 2015 and December 2015. Subjects were divided in two groups: CHC group, defined as CHC use for ≥6 months, and control group, defined as ...
Rabiolo A., Corvi F., Monteduro D., Benatti L., Cicinelli M. V., Fogliato G., Querques G., Bandello F.   +7 more
openaire   +3 more sources

Self-injection of monthly combined hormonal contraceptive

Contraception, 2006
The monthly injectable contraceptive is usually administered in the office. We aimed to compare home self-injection with office administration with respect to satisfaction, compliance, and time and money spent on contraceptive behavior.We enrolled 16 subjects and taught them self-injection for a prospective cohort trial with crossover.
Nancy L, Stanwood, Kara, Eastwood, Alison, Carletta   +2 more
openaire   +2 more sources

Combined Hormonal Contraceptives and Venous Thromboembolism

Obstetrics & Gynecology, 2012
To date, 13 studies have provided data on the risk of venous thromboembolism associated with combined oral contraceptives containing drospirenone or the norelgestromin-containing contraceptive patch. The studies varied in their conclusions about whether these methods are associated with higher risks than combined oral contraceptives containing other ...
Elizabeth G, Raymond, Anne E, Burke, Eve, Espey   +2 more
openaire   +2 more sources

The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives

American Journal of Obstetrics and Gynecology, 2011
Discussion of effective birth control methods can be a challenging process for clinicians because the adoption and consistent use of contraception may be influenced by patients' fears, myths, and misperceptions. Over the years, new progestins have been included in combination contraceptives or are used alone to provide effective contraception as well ...
openaire   +2 more sources

Combined Hormonal Contraception

2014
Combination hormonal contraceptives, i.e., oral contraceptive pills, the contraceptive vaginal ring, and the contraceptive patch, are used by approximately 70 % of sexually active teenagers. These methods have unique advantages and disadvantages when used by this population.
openaire   +1 more source

Benefits and risks of combined hormonal contraception

Prescriber, 2022
Since the introduction of the Pill over 60 years ago, combined hormonal contraception (CHC) has remained one of the most popular forms of contraception. This article outlines the choice of CHC available, including different formulations of the combined oral contraceptive pill, the transdermal patch and the vaginal ring, and discusses the benefits and ...
openaire   +1 more source

A New Year-Long Combination Hormonal Contraceptive

Nursing for Women's Health, 2019
The U.S. Food and Drug Administration approved a new combination hormonal contraceptive in August 2018. Sold under the brand name Annovera, it is a combination of segesterone acetate and ethinyl estradiol, and it is the first multiuse vaginal contraceptive system that prevents ovulation for up to 13 menstrual cycles in a year.
openaire   +2 more sources

Migraine and Use of Combined Hormonal Contraception

2019
Migraine onset and activity in women are influenced by the fluctuations of sex hormone levels, particularly estrogen. According to the “estrogen withdrawal hypothesis,” migraine episodes are precipitated by a decline in estrogen, as may occur in the menstrual period [1].
Francesca Pistoia, Simona Sacco
openaire   +1 more source

There is no association between combined oral hormonal contraceptives and depression: a Swedish register‐based cohort study

BJOG: an International Journal of Obstetrics and Gynaecology, 2022
Cecilia Lundin, E Lampa, Marie Bixo
exaly